Source comparison
MK-677 vs HGH Injections Mechanism: Research Application Comparison
Primary Pathway Ghrelin receptor agonism → pituitary GH release Direct exogenous GH → systemic circulation MK-677 maintains endogenous regulation; HGH overrides it Pulsatile Secretion Preserves natural GH pulse amplitude and frequency Flattens pulsatility with
This comparison does not assign a generated winner or score.
- Primary Pathway
- Ghrelin receptor agonism → pituitary GH release
- Direct exogenous GH → systemic circulation
- MK-677 maintains endogenous regulation; HGH overrides it
- Pulsatile Secretion
- Preserves natural GH pulse amplitude and frequency
- Flattens pulsatility with sustained elevation
- Pulsatile exposure may preserve receptor sensitivity longer
- Suppression Risk
- No suppression of endogenous GH production
- Complete pituitary suppression within 2–4 weeks
- MK-677 allows immediate cessation; HGH requires tapering
- Administration
- Oral, once daily
- Subcutaneous injection, daily or twice daily
- MK-677 eliminates injection protocol complexity
- IGF-1 Elevation
- 60–90% increase at 25mg/day
- 200–400% increase at 4 IU/day
- HGH achieves higher IGF-1 but at cost of axis suppression
- Receptor Sensitivity
- Maintained over 6+ months of continuous use
- Declines after 12+ weeks without dose escalation
- MK-677 shows stable response curves in long-term studies
- Metabolic Side Effects
- Appetite increase, potential insulin resistance
- Direct insulin antagonism, impaired glucose tolerance
- Both require glucose monitoring; HGH effect is dose-dependent